Literature DB >> 3168352

Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods.

S A Halperin1, S A Heifetz, A Kasina.   

Abstract

The mouse respiratory model is being used increasingly to study the pathogenesis and immunology of Bordetella pertussis infection. Two methods of inoculation, aerosol and intranasal, are routinely used to establish the infection. We compared the two methods of inoculation for reproducibility of infection using quantitative lung cultures and distribution of infection with [35S] methionine labeled bacteria and pulmonary histopathology. Ability to produce a respiratory infection intranasally was related to the inoculum volume; a minimum of 20 microliters was required although considerable variability remained. Lung bacterial counts in identically inoculated mice varied 1,000 fold following intranasal inoculation compared to only 5 fold following aerosol inoculation. Distribution of pulmonary 35S-labeled bacteria varied widely (right lung, 43-84%; left lung 16-57%) following intranasal in comparison to aerosol inoculation (right, 60-68%; left 32-40%). Finally, intranasal inoculation produced a scant, patchy, bronchopneumonia whereas diffuse pathology involving all pulmonary segments was seen following aerosol infection. Due to the superior reproducibility and predictable distribution of infection and pathology, aerosol inoculation is the method of choice for establishing the mouse model of pertussis respiratory infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168352

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  13 in total

1.  Lethal infection by Bordetella pertussis mutants in the infant mouse model.

Authors:  A A Weiss; M S Goodwin
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

2.  Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.

Authors:  J B Bruss; G R Siber
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

3.  Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.

Authors:  Steven B Yee; Joshua M Hatkin; David N Dyer; Steven A Orr; M Louise M Pitt
Journal:  Comp Med       Date:  2010-12       Impact factor: 0.982

4.  Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Amanda D Goudie; Warren H Finlay; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

5.  Development of a rat model for respiratory infection with Bordetella pertussis.

Authors:  D E Woods; R Franklin; S J Cryz; M Ganss; M Peppler; C Ewanowich
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

6.  Murine aerosol challenge model of anthrax.

Authors:  Crystal L Loving; Mary Kennett; Gloria M Lee; Vanessa K Grippe; Tod J Merkel
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

7.  Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model.

Authors:  Marc Mansour; Robert G Brown; Annette Morris; Bruce Smith; Scott A Halperin
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model.

Authors:  Jon B Bruss; George R Siber
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits.

Authors:  Steven B Yee; David N Dyer; Nancy A Twenhafel; M Louise M Pitt
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 10.  The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Karlene H Lynch; Jonathan J Dennis
Journal:  Front Cell Infect Microbiol       Date:  2012-01-20       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.